{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-208965","form_type":"8-K","ticker":"BTMD","cik":"0001819253","company_name":"biote Corp.","filed_at":"2026-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.991949+00:00","generated_at":"2026-05-14T22:52:07.466073+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biote Q1 revenue $44.9M (-8.3% YoY); net income $2.7M vs $15.8M, hit by hormone pellet recall","bullets":["Revenue $44.9M, down 8.3% YoY; net income $2.7M ($0.06 EPS) vs $15.8M ($0.37) in Q1 2025.","Procedure revenue fell 13.2% to $31.3M due to voluntary recall of Asteria Health hormone pellets; supplements up 19.1% to $11.0M.","Gross margin 68.9% vs 74.3% from higher replacement costs and reduced manufacturing efficiency at Asteria.","Adjusted EBITDA $8.7M (19.4% margin); sales team expansion nearing target of 120 representatives.","Management expects return to procedure growth in second half of 2026 after recall impact."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-208965","json":"https://secwatch.observer/filing/0001193125-26-208965.json","markdown":"https://secwatch.observer/filing/0001193125-26-208965.md","text":"https://secwatch.observer/filing/0001193125-26-208965.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819253/000119312526208965/0001193125-26-208965-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819253/000119312526208965/btmd-20260506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:52:07.466073+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3ee075d2ea208abc9f3c33415b2058c0da93a83c","claim":"biote Corp. reported the first quarter ended March 31, 2026 results: revenue Revenue of $44.9 million, net income Net income of $2.7 million, EPS diluted earnings per share attributable to biote Corp. stockholders of $0.06.","evidence_excerpt":"Results Sales team expansion on track and nearing targeted level Return to procedure growth expected in second half of 2026 First Quarter 2026 Financial Highlights • Revenue of $44.9 million • Gross profit margin of 68.9% • Net income of $2.7 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $15.8","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819253/000119312526208965/0001193125-26-208965-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"Revenue of $44.9 million"},{"label":"Net income","value":"Net income of $2.7 million"},{"label":"EPS","value":"diluted earnings per share attributable to biote Corp. stockholders of $0.06"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}